Abstract Objective This study aimed to explore the anti‐skin aging efficacy of a novel serum containing acetyl hexapeptide‐8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract through one ex‐vivo study and two clinical studies. Methods In ex‐vivo study, skin samples were exposed to the serum (Formula 1) and its active ingredient combinations (Formula 2). Biomarkers including matrix metalloproteinase‐1, elastic fibres and collagen types I, III, IV and XVII content were analyzed to evaluate the efficacy. In clinical study 1 ( n = 50), the Formula 1's efficacy in reducing static wrinkles and improving skin quality was examined, while study 2 ( n = 42) focused on its efficacy against dynamic wrinkles. Results Formula 1 significantly increased levels of anti‐aging biomarkers including elastic fibres, collagen fibres, etc. Meanwhile, Formula 1 significantly improved static wrinkle appearance within the first week, with mean clinical scoring from 35% to 69% for various types of wrinkles after 12 weeks of use (all p < 0.001). The clinical scoring for dynamic wrinkles improved by 10%–13% (all p < 0.001). Additionally, significant improvements were observed in skin quality, indicated by clinical scoring changes of smoothness (30%), radiance (27%), skin pore (43%), elasticity (33%) and firmness (36%) (all p < 0.001). Conclusion The serum demonstrates significant anti‐aging effects, effectively improving static and dynamic wrinkles and skin quality.
Zhu et al. (2026) studied this question.